| Aggressive Systemic Mastocytosis
Ayvakit vs Rydapt
Side-by-side clinical, coverage, and cost comparison for aggressive systemic mastocytosis.Deep comparison between: Ayvakit vs Rydapt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRydapt has a higher rate of injection site reactions vs Ayvakit based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rydapt but not Ayvakit, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ayvakit
Rydapt
At A Glance
Oral
Daily
KIT/PDGFRA kinase inhibitor
Oral
Twice daily
Multi-kinase inhibitor
Indications
- Gastrointestinal Stromal Tumors
- Aggressive Systemic Mastocytosis
- Indolent Systemic Mastocytosis
- Leukemia, Myelocytic, Acute
- Aggressive Systemic Mastocytosis
- Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease
- Leukemia, Mast-Cell
Dosing
Gastrointestinal Stromal Tumors 300 mg orally once daily in patients with PDGFRA exon 18 mutation-positive unresectable or metastatic GIST; continue until disease progression or unacceptable toxicity.
Aggressive Systemic Mastocytosis 200 mg orally once daily; continue until disease progression or unacceptable toxicity.
Indolent Systemic Mastocytosis 25 mg orally once daily.
Leukemia, Myelocytic, Acute 50 mg orally twice daily with food on Days 8 to 21 of each induction cycle with cytarabine and daunorubicin and on Days 8 to 21 of each consolidation cycle with high-dose cytarabine.
Aggressive Systemic Mastocytosis, Systemic mastocytosis with associated clonal, hematologic non-mast-cell lineage disease, Leukemia, Mast-Cell 100 mg orally twice daily with food; continue until disease progression or unacceptable toxicity.
Contraindications
—
- Hypersensitivity to midostaurin or any excipient, including reactions such as anaphylactic shock, dyspnea, flushing, chest pain, and angioedema
Adverse Reactions
Most common (>=20%) in GIST edema, nausea, fatigue/asthenia, cognitive impairment, vomiting, decreased appetite, diarrhea, increased lacrimation, abdominal pain, constipation, rash, dizziness, hair color changes
Most common (>=20%) in AdvSM edema, diarrhea, nausea, fatigue/asthenia
Most common (>=10%) in ISM eye edema, dizziness, peripheral edema, flushing
Serious intracranial hemorrhage, anemia, pleural effusion, sepsis, gastrointestinal hemorrhage, subdural hematoma, ascites, pneumonia, acute kidney injury, encephalopathy
Most common (>=20%) - AML Febrile neutropenia, nausea, mucositis, vomiting, headache, petechiae, musculoskeletal pain, epistaxis, device-related infection, hyperglycemia, ECG QT prolonged, upper respiratory tract infections
Most common (>=20%) - Systemic Mastocytosis Nausea, vomiting, diarrhea, edema, musculoskeletal pain, abdominal pain, fatigue, upper respiratory tract infection, constipation, pyrexia, headache, dyspnea
Serious Pulmonary toxicity, febrile neutropenia, sepsis, gastrointestinal hemorrhage, pneumonia, cardiac events
Postmarketing Interstitial lung disease, acute febrile neutrophilic dermatosis (Sweet syndrome)
Pharmacology
Avapritinib is a tyrosine kinase inhibitor that targets KIT D816V, PDGFRA, and PDGFRA D842 mutants (IC50s <25 nM), inhibiting autophosphorylation and constitutive activation of these receptors to suppress tumor and mast cell proliferation; other potential targets include wild-type KIT, PDGFRB, and CSFR1.
Midostaurin is a multi-kinase inhibitor that inhibits wild type and mutant FLT3, KIT (wild type and D816V), PDGFRalpha/beta, and members of the PKC serine/threonine kinase family, inducing apoptosis in leukemic cells expressing FLT3 mutations and inhibiting KIT signaling and histamine release in mast cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ayvakit
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
No coverage data available for Rydapt.
UnitedHealthcare
Ayvakit
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
No coverage data available for Rydapt.
Humana
Ayvakit
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
No coverage data available for Rydapt.
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gastrointestinal Stromal Tumors (GIST) - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Novartis Oncology Universal Co-pay Program: RydaptCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AyvakitView full Ayvakit profile
RydaptView full Rydapt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.